\*\*\* RECEIVED \*\*\*
Nov 25,2003 14:19:41 WS# 0
OFFICE OF THE SECRETARY
CORRESPONDENCE
CONTROL CENTER



RECEIVED

03 NOV 25 AM 11: 53

DELICE OF THE SECRETARY COMMUNICATIONS CONTROL CENTER

2002-A Guadalupe St. Suite 284 Austin, TX 78705 www.americanfreedom.org Phone: (512) 453-7989 Fax: (512) 453-7990

Marc Levin, Esq. President Austin, TX

Royal Masset, Esq. Senior Fellow Austin, TX

Todd Stein, CFA Senior Fellow Chicago, IL

Brent Tantillo, Esq. Senior Fellow Washington, D.C.

**David Rogers, Esq.** Senior Fellow Austin, TX

Hal Siemer Senior Fellow Austin, TX

Steven Wales, Esq. Senior Fellow Houston, TX

Charles Ganske Fellow Austin, TX

Brendan Steinhauser Fellow Austin, TX November 18, 2003

The Honorable Tommy Thompson U.S. Department of Health and Human Services 200 Independence Avenue, S.W. Washington, D.C. 20201

Dear Mr. Secretary,

On behalf of the American Freedom Center, a conservative public policy institute supporting lower taxes, self-reliance, and strong families, I applaud your many policy achievements as Governor of Wisconsin and now as Secretary of Health and Human Services. I am writing today in connection with a petition filed by WellPoint Health Networks, Inc. that is currently being considered (Docket # 98P-0610) that would force the manufacturers of Allegra and Zyrtec to move these medications from prescription status to over-the-counter.

To the extent you are involved in this matter, we wish to let you know that we oppose this petition and are concerned about the increased out-of-pocket costs that Americans who use these medications will be faced with should it be approved. Insurance companies have an interest in moving as many drugs as possible to over-the-counter status because coverage is less or non-existent in most policies for over-the-counter medications.

As supporters of free market policies, we believe it should be up to each pharmaceutical company to decide how and where it wishes to market its products. While the federal government can encourage companies to make certain decisions in this regard, federal mandates that drugs must go from prescription status to over-the-counter are little different than requiring Lexus vehicles to be sold at Ford dealers because the latter dealers have a lower mark-up above the invoice.

Furthermore, as an organization that is concerned with the effects of out-of-control litigation on the business climate, we would point out that Andrew Krulwich, a lawyer who specializes in food and drug-law regulation, told the *Boston Herald* on September 14, 2003 that forcing switches could raise costs by exposing drug makers to unwanted product liability risks.

Thank you very much for your consideration.

Nov 25,2003 14:19:41 WS# 06
OFFICE OF THE SECRETARY
CORRESPONDENCE
CONTROL CENTER

Sincerely,

President